Reshaping the HIV treatment and prevention landscape

Extensive technology platform portfolio across R&D Unlocking the synergy between vaccines and specialty medicines gsk AS MIN PROTEIN M Antigen Anlicens Antiger-Lir dry agent Antibody Protein +/- adjuvant mRNA Glycoconjugate Viral vector Monoclonal antibodies Underpinned by our focus on the science of the immune system MM Human genetics & functional genomics 60

View entire presentation